Table 3.
Icatibant treatment outcomes
| Endpoint | Patients with HAE‐C1‐INH | ||||||
|---|---|---|---|---|---|---|---|
| Germany (N = 42) | Other countriesa (N = 251) | ||||||
| n b | Mean (SD) | Median (IQR) | n b | Mean (SD) | Median (IQR) | P‐valuec | |
| Time from attack onset to treatment, hd | 160 | 1.3 (4.7) | 0.0 (0.0–0.5) | 1422 | 4.2 (7.2) | 1.5 (0.5–5.0) | <0.0001 |
| Time to complete symptom resolution, he | 160 | 7.6 (12.2) | 3.0 (1.0–8.5) | 1422 | 15.1 (19.6) | 7.0 (2.5–20.5) | <0.0001 |
| Duration of attack, hf | 160 | 8.9 (13.2) | 4.3 (1.0–10.0) | 1422 | 19.3 (22.3) | 10.5 (5.0–25.5) | <0.0001 |
a
Other countries include Austria, Brazil, Czech Republic, Denmark, France, Greece, Israel, Italy, Spain, Sweden and United Kingdom.
b
Attacks with complete data for time to treatment, time to complete resolution and attack duration, excluding attacks treated 100 h after attack onset.
c
Mixed model analysis of repeated measures comparing attacks in German vs. non‐German patients.
d
Time between the start of the attack and time to first icatibant injection.
e
Time between first injection of icatibant and complete resolution of symptoms.
f
Time between start of onset of attack and complete resolution of symptoms.
HAE, hereditary angioedema; IQR, interquartile range; SD, standard deviation.